The $3.40 Target Is Right. The Market's $1.63 Price Is Still Worried About the Wrong Thing.

The Simply Wall St fair value model just cut Pulmonx to $3.40 from $5.17. The stock is at $1.63. Both numbers are right - and that is the point.

The model's cut reflects a more honest revenue and margin assumption. The stock's price reflects a market still pricing Pulmonx as a company whose business is deteriorating. The numbers from the July 29 Q2 report say otherwise.

The Old Story vs. The Operating Reality

The old story is simple: declining revenue, cash burn, a battered sales force. It's not wrong. It just doesn't tell the whole picture anymore.

Q2 revenue was $22.8 million, down 5% year over year. U.S. revenue fell 4%. On those lines, the decline narrative is fair. But gross margin hit a record 78%, up from 72% a year ago. Net loss fell 34%, from $15.2 million to $10.1 million. Adjusted EBITDA loss (earnings before interest, taxes, depreciation, and amortization - a rough proxy for cash earnings) narrowed 39% to $5.1 million. Operating expenses dropped 16% to $26.8 million.

The top line is still soft. The bottom line is accelerating. That divergence is the inflection signal.

More important, the sequential direction turned. U.S. revenue rose 7% from Q1 to Q2, from $13.3 million to $14.2 million. Pulmonx added 12 U.S. treating centers in the quarter. All sales leadership positions are now filled. The CEO said turnover has normalized after running two to three times industry average last year. New reps typically take six to nine months to ramp - so the reps hired in Q1 should be hitting stride in Q3 and Q4.

The China hole is closing too. Pulmonx renewed its Chinese registration certificate in June. Distributor shipments resume in early 2027. International revenue excluding China grew 12% year over year in Q2. When China comes back, even modestly, the ex-China momentum compounds.

What the Market Is Missing

Investors are looking at top-line decline and cash burn and seeing a company that keeps getting worse. They're not seeing the mechanics of a business whose cost structure has been realigned, whose gross margins are at a record high, and whose sequential revenue trend just flipped positive in the U.S.

Management guided full-year 2026 revenue to $90-92 million. H1 revenue was $43.4 million ($20.6M + $22.8M). That means H2 needs roughly $47-49 million, or about $23.5-24.5 million per quarter. The Q2 run rate of $22.8 million is already in the ballpark - the sequential uptrend and rep ramp are doing the heavy lifting.

Gross margin guidance was raised to approximately 76% for the full year (from the prior ~75% expectation set in Q1). Operating expense guidance was lowered to $109-111 million. Pulmonx continues to expect cash, cash equivalents, and marketable securities to decrease by roughly $23 million for the year, in line with its Q1 guidance. The company entered Q2 with $61.6 million in cash and ended it with $55.8 million. With $74.2 million in total debt and a 2031 maturity on the credit facility, there's no near-term solvency risk.

This is the operating leverage the market needs to feel comfortable with before it stops pricing Pulmonx as a turnaround in search of a bottom.

The Financial Bridge

I don't use DCF models - they give the illusion of control. Simple forward multiples are cleaner.

At $3.40 per share, Pulmonx is valued at roughly $144 million on roughly 42.2 million shares outstanding (inferred from a $68.9 million market cap at $1.63). That's about 1.57 times the $92 million top end of 2026 revenue guidance. For a medical device company with 76-78% gross margins and narrowing losses, that's not a stretch - it's a patient multiple that says you believe the loss compression continues into 2027.

Here's the path - and it's the one the published $3.40 target is built on.

The $3.40 target is a 12-month number. It assumes Q3 and Q4 hit the sequential trajectory, China shipments restart in early 2027, and loss compression stays on track. It does not require a revenue miracle - just the execution Pulmonx has already shown in Q2.

The AInvest Frame

AInvest's aggregate signal still labels Pulmonx a Buy, though its fundamental rating sits at 0.4 out of 10 - essentially the lowest tier. That split is telling. The composite analysis (5.94/10) reflects the growth and optionality in the story. The fundamental score captures the GAAP losses and negative returns that the financial statements still show. The market hasn't reconciled these two signals yet, which is why the stock is at $1.63 while the model says $3.40.

What Could Break It

The thesis is concrete, which means the invalidation conditions are too:

• Sequential U.S. revenue falls in Q3. The whole ramp argument hinges on the new sales team gaining momentum. If Q3 U.S. revenue declines from the $14.2 million Q2 level, the rep ramp is stalling and the sequential inflection thesis is stale.
• Operating expenses blow past the $111 million guidance ceiling. If cost discipline slips, the loss compression story unrinds and cash burn accelerates. Management lowered its own guidance, which is a good sign - but the market will punish a miss here.
• China restart slips materially beyond early 2027. The ex-China growth is real, but China was a non-trivial contributor to total revenue. A significant delay narrows the 2027 growth path.
• Cash drops below $25 million by year-end with no clarity on burn. Solvency isn't at risk now with the 2031 debt maturity, but a cash position that drops faster than guided would force dilution concerns.

The Setup

The market is still pricing the old story - a declining revenue company burning cash with a broken sales force. The Q2 report says the sales force is being rebuilt, gross margins are at a record high, losses are compressing fast, and U.S. revenue turned positive sequentially.

The $3.40 target is a patient multiple on a business that is closing the gap toward breakeven faster than the price reflects. It's not a bet on a revenue breakout. It's a bet that the cost structure and margin trajectory are real, and the rep ramp delivers what the sequential data already hints at.

If Q3 continues the trajectory, the gap between $1.63 and $3.40 is the market catching up to numbers it already has. If Q3 U.S. revenue falls sequentially, cut it. Discipline over ego.

No target forces the issue. But when the financial bridge is explicit - and this one is - you put a number on it, a date, and a condition for being wrong. The setup is the operating leverage showing up in Q2 while the stock still trades like the business is broken.